Categoria: Scientific Paper

Mortality outcomes of vertebral augmentation (vertebroplasty and/or balloon kyphoplasty) for osteoporotic vertebral compression fractures: a systematic review and meta-analysis

  • Autori: Hinde K, Maingard J, Hirsch JA, Phan K, Asadi H, Chandra RV.
  • Data di pubblicazione: 27/11/24
  • Share on

Categorie

Contattaci

Vuoi metterti in contatto diretto con noi?

-

Authors

Hinde K, Maingard J, Hirsch JA, Phan K, Asadi H, Chandra RV.

Institute

Department of Radiology / Interventional Radiology – Australian Hospitals.

Journal

Radiology. 2020 Apr;295(1):96-103.

Take Home message

  • Vertebral augmentation in case of osteoporotic fracture reduces significantly mortality by 22% compared to conservative treatment.
Study details   Score Range
Subject Clinical - -
Type Systematic review and meta-analysisy 3 1 - 5
Journal Radiology 3 1 - 3

Summary

Literature was analyzed and a meta-analysis was performed on mortality outcomes of patients with OVCF treated with vertebral augmentation (VA) compared with patients treated with non-surgical management (NSM)

Sample characteristics

> 2 million patients
16 studies (USA, Austria, Germany, UK, Australia, Taiwan, China)

Database

PubMed, EMBASE, Cochrane

Method

PRISMA

Quality Assessment

Newcastle-Ottawa Scale

Mortality benefit

More evident in large sample studies
Consistent across both 2- and 5-year follow-up periods

96.8% (30/31) vs 92.5% (37/40)


Heterogeneity

Substantial across study samples


Sensitivity analysis

No single study was a key contributor to heterogeneity

Bias (Egger test)

Results for publication bias were not significant (P=0.23)

Comments

NSM involves bed rest, opioids analgesia, muscle relaxants, back braces. All these carry adverse risks.
VA may provide mortality benefit by avoiding prolonged NSM through pain relief and reduced deformity.

Key points

Hazard ratios for mortality benefit for VA vs NSM across 2- and 5-year periods was 0.70 (P<0.001) and 0.79 (P=0.05), respectively
Pooled hazard ratio for mortality comparing VA with NSM was 0.78 (P =0 .003) at up to 10 years.
BKP provided a mortality benefit over PVP in the treatment of OVCF with hazard ratio of 0.77 versus 0.87 (P< 0.001)

Study score and Journal

Study value Description
* Retrospective study
* * Retrospective comparative
Retrospective Register study
* * * Prospective study
Systematic review
Meta-analysis
* * * * Randomized controlled trial (RCT)
* * * * * Systematic review of RCT
Journal value Description
* Low impact factor (<1.500)
* * Medium impact factor (>1.500 – <2.500)
* * * High impact factor (> 2.500)

Attenzione

State per accedere ad un'area riservata SOLO agli operatori del settore medico. Requisiti regolatori e norme mediche possono variare da Stato a Stato, così come le informazioni legali e la protezione dei dati personali. Le informazioni presenti nell'area cui state per accedere potrebbero non essere appropriate all'uso nel vostro Stato. Cliccando su Continua, confermate di essere operatori del settore medico e di aver compreso che lo statuto legale e le politiche di privacy possono essere diverse da quelle del vostro Paese.

Confermi l'iscrizione a questo evento?